Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
GTXI's Cash to Debt is ranked higher than
97% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. GTXI: No Debt )
GTXI' s 10-Year Cash to Debt Range
Min: 1890.4   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GTXI's Interest Coverage is ranked higher than
76% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GTXI: No Debt )
GTXI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -28.69
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -394.15
GTXI's ROE (%) is ranked lower than
51% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. GTXI: -394.15 )
GTXI' s 10-Year ROE (%) Range
Min: -3571.43   Max: 29.57
Current: -394.15

-3571.43
29.57
ROA (%) -269.86
GTXI's ROA (%) is ranked lower than
52% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. GTXI: -269.86 )
GTXI' s 10-Year ROA (%) Range
Min: -269.86   Max: 23.8
Current: -269.86

-269.86
23.8
ROC (Joel Greenblatt) (%) -38927.68
GTXI's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. GTXI: -38927.68 )
GTXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -38927.68   Max: 682.89
Current: -38927.68

-38927.68
682.89
Revenue Growth (%) -100.00
GTXI's Revenue Growth (%) is ranked higher than
51% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. GTXI: -100.00 )
GTXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 98.3
Current: -100

0
98.3
» GTXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

GTXI Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

GTXI Guru Trades in Q4 2013

Jim Simons 18,480 sh (New)
Paul Tudor Jones 44,285 sh (New)
» More
Q1 2014

GTXI Guru Trades in Q1 2014

Paul Tudor Jones 44,285 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

GTXI Guru Trades in Q2 2014

George Soros 38,828 sh (New)
Paul Tudor Jones 44,285 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.3 - $1.66 $ 0.96-32%38828
George Soros 2011-12-31 Sold Out 0.01%$2.36 - $4.61 $ 0.96-72%0
George Soros 2011-09-30 New Buy0.01%$2.78 - $4.92 $ 0.96-75%150000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.80
GTXI's P/B is ranked higher than
65% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. GTXI: 4.80 )
GTXI' s 10-Year P/B Range
Min: 1.18   Max: 32.88
Current: 4.8

1.18
32.88
EV-to-EBIT -1.45
GTXI's EV-to-EBIT is ranked higher than
64% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GTXI: -1.45 )
GTXI' s 10-Year EV-to-EBIT Range
Min: 3.8   Max: 12.8
Current: -1.45

3.8
12.8
Current Ratio 4.98
GTXI's Current Ratio is ranked higher than
76% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. GTXI: 4.98 )
GTXI' s 10-Year Current Ratio Range
Min: 3.13   Max: 21.23
Current: 4.98

3.13
21.23
Quick Ratio 4.98
GTXI's Quick Ratio is ranked higher than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GTXI: 4.98 )
GTXI' s 10-Year Quick Ratio Range
Min: 3.12   Max: 21.22
Current: 4.98

3.12
21.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.40
GTXI's Price/Net Cash is ranked higher than
85% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GTXI: 5.40 )
GTXI' s 10-Year Price/Net Cash Range
Min: 2.7   Max: 307.67
Current: 5.4

2.7
307.67
Price/Net Current Asset Value 5.40
GTXI's Price/Net Current Asset Value is ranked higher than
84% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. GTXI: 5.40 )
GTXI' s 10-Year Price/Net Current Asset Value Range
Min: 2.68   Max: 153.83
Current: 5.4

2.68
153.83
Price/Tangible Book 5.10
GTXI's Price/Tangible Book is ranked higher than
69% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. GTXI: 5.10 )
GTXI' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 43.95
Current: 5.1

2.6
43.95
Price/Median PS Value 0.20
GTXI's Price/Median PS Value is ranked higher than
97% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. GTXI: 0.20 )
GTXI' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 6.76
Current: 0.2

0.04
6.76
Forward Rate of Return (Yacktman) -69.59
GTXI's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. GTXI: -69.59 )
GTXI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -42.6   Max: -21.8
Current: -69.59

-42.6
-21.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GTU.Germany
GTx, Inc. is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. The company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The company's most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. It plans to build a specialty sales and marketing infrastructure, for marketing its products.
» More Articles for GTXI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: GTx, Inc, VIVUS, Inc, Time Warner Inc. Jul 22 2012 
Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx Apr 16 2012 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2010 
GTx Inc. Reports Operating Results (10-Q) Aug 09 2010 
GTx Inc. Reports Operating Results (10-Q) May 04 2010 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2009 
GTx Inc. Reports Operating Results (10-Q) Aug 10 2009 
GTx, Inc. Reports Second Quarter 2009 Corporate Results Aug 10 2009 
GTx Inc. Reports Operating Results (10-Q) May 11 2009 
GTX Reports Fourth Quarter and Year End 2008 Results Feb 17 2009 

More From Other Websites
GTX INC /DE/ Financials Aug 15 2014
GTx Announces Webcast of Corporate Presentation at the 2014 Wedbush Pacgrow Life Sciences Management... Aug 07 2014
GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results Aug 05 2014
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 05 2014
Q2 2014 GTx, Inc. Earnings Release - Before Market Open Aug 05 2014
GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results Aug 05 2014
GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014 Jul 22 2014
GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014 Jul 22 2014
GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Jun 12 2014
GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 02 2014
GTx reports results from Phase 2 study of enobosarm Jun 02 2014
GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with... Jun 02 2014
GTX Inc. (GTXI) Soars: Stock Up 9.7% May 29 2014
GTx Announces Webcast of Corporate Presentation at Jefferies 2014 Global Healthcare Conference May 22 2014
GTx to Present Clinical Data on Enobosarm in Breast Cancer and NSCLC at ASCO 2014 Annual Meeting May 19 2014
GTx files to sell $150M of common stock, warrants May 12 2014
GTX INC /DE/ Files SEC form 10-Q, Quarterly Report May 12 2014
GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles... May 09 2014
GTx says current POWER trials data insufficient to support filing NDA May 08 2014
GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide